The PRADA (Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy) II study (NCT03760588), led by the same team that carried out the original PRADA study, is investigating entresto, a combination medication for heart failure that combines a neprilysin inhibitor and an ARB. Here, MME is linked to breast carcinoma.